Benchling began over a decade ago in an academic lab at MIT, when we realized that the technology needed to support the complexity and pace of science wasn't available. So we created our own, with modern science and collaboration in mind.Today, Benchling serves the world’s biotech leaders and innovators, big and small. Our team wakes up every day focused on helping our global customers unlock the power of biotechnology faster, whether they're developing new medicines, crops, foods, or materials. The biotech revolution is happening today and Benchling powers the possibilities of tomorrow.
In the early days, most software investors were not excited about biotechnology. But one investor who was curious about biotechnology was Y Combinator. Paul Graham wasn’t bothered by our originally narrow focus. I remember him saying that people who work with biology are important and so to be the most important software for them will surely turn out to be valuable.